ArticleEJHaem2026
A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data for the use of rituximab, gemcitabine, and oxaliplatin (R-GemOx) for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R-GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record-derived database comprising patient-level data primarily from US community oncology practices. Methods: Patients diagnosed with LBCL who initiated treatment with R-GemOx in the second or later line of therapy between 2011 and 2023, were included. Patient characteristics, treatment patterns, and efficacy outcomes were assessed. Results: Of 281 patients, most (66.2%) were treated at community centers. Overall response rate was 45.4% (95% confidence interval [CI]: 38.1-52.9); complete response (CR) rate was 22.2% (95% CI: 16.4-28.8). Median progression-free and overall survival (OS) were 2.8 months (95% CI: 2.6-3.7) and 12.7 months (95% CI: 10.6-17.1), respectively. In patients who received R-GemOx in the second line, the CR rate was higher and the median OS was longer versus those who received it in later lines (CR rate, 26.3% vs. 17.4%; median OS, 19.6 vs. 10.0 months, respectively). Conclusion: These data offer a real-world benchmark for patterns of use and outcomes of R-GemOx in patients with R/R LBCL in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.